Skip to main content
Log in

Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of cushing's disease with low doses

European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary.

Mitotane (o,p'-DDD) can be used for the treatment of various adrenocortical diseases such as Cushing's syndrome, but the usual doses of 6–8 g per day are often associated with severe adverse effects.

This paper reports the results of much lower doses of o,p'-DDD (0.5–2 g per day) in two patients with Cushing's disease over periods of 8 and 5 years, respectively, under concomitant monitoring of the plasma levels of the parent drug and its major metabolite, o,p'-DDE.

It became apparent that o,p'-DDD and o,p'-DDE have a strong tendency to accumulate in the body due to their high lipophilicity. As a consequence, changes in dose regimens had long lag times before they were reflected in plasma levels and once an increase or decrease had started one had to be careful not to cause overshoot.

Steady state plasma levels of o,p'-DDD between 5–10 μg/ml appeared sufficient to induce and to maintain remission of the disease, which was accompanied with normal cortisol levels in plasma and urine. DDD-levels below 5 μg/ml for several weeks may lead to relapses, whereas DDD-levels over 10 μg/ml gave rise to side effects. On the other hand, o,p'-DDE seemed inactive at levels up to 4 μg/ml in plasma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bergenstal DM, Hertz R, Lipsett MB, Moy RH (1960) Chemotherapy of adrenocortical cancer with o,p'-DDD. Ann Intern Med 53: 672–682

    Google Scholar 

  2. Hutter AM, Kayhoe DE (1966) Andrenal cortical carcinoma. Results of treatment with o,p'-DDD in 138 patients. Am J Med 41: 581–592

    Google Scholar 

  3. Lubitz JA, Freeman L, Okun R (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223: 1109–1112

    Google Scholar 

  4. Orth DN, Liddle GW (1971) Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 285: 234–247

    Google Scholar 

  5. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC (1978) o,p'-DDD (Mitotane) therapy of adrenal cortical carcinoma. Cancer 42: 2177–2181

    Google Scholar 

  6. Van Slooten H, Moolenaar AJ, Van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20: 47–53

    Google Scholar 

  7. Southren AL, Weisenfeld S, Laufer A, Goldner MG (1961) Effect of o,p'-DDD in a patient with Cushing's syndrome. J Clin Endocrinol Metab 21: 201–208

    Google Scholar 

  8. Temple TE, Jones DJ, Liddle GW, Dexter RN (1969) Treatment of Cushing's disease. Correction of hypercortisolism by o,p'-DDD without induction of aldosterone deficiency. N Engl J Med 281: 801–805

    Google Scholar 

  9. Luton JP, Mahoudeau JA, Bouchard PH, Thieblot P, Haute-couverture M, Simon D, Laudat MH, Touitou Y, Bricaire H (1979) Treatment of Cushing's disease by o,p'-DDD. N Engl J Med 300: 459–464

    Google Scholar 

  10. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA (1980) Sustained remission of Cushing's disease with Mitotane and pituitary irradation. Ann Internal Med 92: 613–619

    Google Scholar 

  11. Keller E, Willgerodt H, Benecke R, Vetter B (1987) Treatment of hypothalamic-pituitary Cushing's disease with o,p'-DDD. Wissenschaftliche Beiträge der Friedrich-Schiller-Universität Jena, p 210–211

  12. Touitou Y, Bogdan A, Luton JP (1978) Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p'-DDD for Cushing's syndrome: Evidence for the sites of action of the drug. J Steroid Biochem 9: 1217–1224

    Google Scholar 

  13. Nissen-Meyer R, Vogt JH (1971) Cushing's syndrome. Diagnosis and treatment. In: Binder C and Hall P (Eds), Chemotherapy. William Heinemann Medical Books, London, p 141

    Google Scholar 

  14. Touitou Y, Bogdan A, Legrand JC, Desgrez P (1977) Métabolisme de l' o,p'-DDD (Mitotane) chez l'homme et l'animal. Ann Endocrin (Paris) 38: 13–25

    Google Scholar 

  15. Moy RH (1961) Studies of the pharmacology of o,p'-DDD in man. J Lab Clin Med 58: 296–304

    Google Scholar 

  16. Moolenaar AJ, Van Seters AP (1975) o,p'-DDD values in plasma and tissues during and after chemotherapy of adrenocortical carcinoma. Acta Endocrinol (Kopenh) [Suppl] 199: 226

    Google Scholar 

  17. Moolenaar AJ, Van Slooten H, Van Seters AP, Smeenk D (1981) Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol 7: 51–54

    Google Scholar 

  18. Van Slooten H, Van Seters AP, Smeenk D, Moolenaar AJ (1982) o,p'-DDD (Mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol 9: 85–88

    Google Scholar 

  19. Keller E, Willgerodt H, Teichmann B, Hoepfner W (1981) Erfahrungen mit o,p'-DDD (Lysodren) bei Behandlung der Nebennierenrinden-Überfunktion im Kindesalter. Kinderärztl Prax 49: 436–441

    Google Scholar 

  20. Benecke R, Vetter B, De Zeeuw RA (1987) Rapid micromethod for the analysis of mitotane and its metabolite in plasma by gas chromatography with electron-capture detection. J Chromatogr 417: 287–294

    Google Scholar 

  21. Müller OA (1983) Operative Therapie des zentralen Cushing-Syndroms. Diagnostik, Operationsindikation und postoperative Ergebnisse. Therapiewoche 33: 6336–6344

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benecke, R., Keller, E., Vetter, B. et al. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of cushing's disease with low doses. Eur J Clin Pharmacol 41, 259–261 (1991). https://doi.org/10.1007/BF00315440

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315440

Key words

Navigation